Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program by Havrdova E, Cohen JA, Horakova D, Kovarova I, Meluzinova E

Get full text

Complement activation in patients with neuromyelitis optica by Nytrova, P, Potlukova, E, Kemlink, D, Woodhall, M, Horakova, D, Waters, P, Havrdova, E, Zivorova, D, Vincent, A, Trendelenburg, M

Complement activation in patients with neuromyelitis optica. by Nytrova, P, Potlukova, E, Kemlink, D, Woodhall, M, Horakova, D, Waters, P, Havrdova, E, Zivorova, D, Vincent, A, Trendelenburg, M

C3a complement split product: possible biomarker of disease activity in patients with neuromyelitis optica by Nytrova, P, Trendelenburg, M, Kemlink, D, Horakova, D, Pavlina, Z, Waters, P, Volna, J, Vincent, A, Havrdova, E, Potlukova, E

Contactin 2 and contactin-associated protein 2 antibodies in patients with multiple sclerosis and clinically isolated syndrome by Nytrova, P, Waters, P, Horakova, D, Hacohen, Y, Kalincik, T, Zbornikova, P, Blahova, J, Krasensky, J, Vaneckova, M, Havrdova, E, Wandinger, K, Vincent, A

Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines (vol 6, pg S1, 1999) by Paty, D, Hartung, H, Ebers, G, SoelbergSorensen, P, Abramsky, O, Kesselring, J, Delwel, G, Miller, A, Korczyn, A, Flechter, S, Milo, R, Levic, Z, Pantovic, M, Guseo, A, Csiba, L, Komoly, S, Havrdova, E, Urbanek, K, Traubner, P, Selmaj, K, Czlonkowska, A, Milonas, I, Karageorgiou, K, Sfaggos, G, Siva, A